Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Nov;84(5):1017-1026.
doi: 10.1007/s00280-019-03925-z. Epub 2019 Sep 3.

Evaluation of the potential for QTc prolongation with avelumab

Affiliations
Meta-Analysis

Evaluation of the potential for QTc prolongation with avelumab

Yulia Vugmeyster et al. Cancer Chemother Pharmacol. 2019 Nov.

Abstract

Purpose: To report integrated electrocardiogram (ECG) summary and exposure-QTc analyses for avelumab, a human immunoglobulin G1 monoclonal antibody that binds programmed cell death 1 ligand 1, to assess potential effects on cardiac repolarization.

Methods: Data were pooled from three-phase 1/2 studies of patients with advanced solid tumors who received avelumab monotherapy (22,000 ECGs from 1818 patients). All analyses used 12-lead singlet ECGs taken using local ECG machines before and approximately 2 h after avelumab infusion on prespecified days. The exposure-QTc and outlier analyses used locally read ECGs; since larger variability is known to be associated with local reading, outlier ECGs were subsequently reevaluated by central read. QTc derived from Fridericia's formula (QTcF) and a project-specific formula (QTcP) were analyzed. Multivariable linear mixed-effects models were used to describe the relationship between serum concentration of avelumab and QTc absolute value or change from baseline (ΔQTc).

Results: Exposure-QTc models showed that the effect of avelumab on QTc or ΔQTc was minimal and not statistically significant for both QTcP and QTcF. In addition, models including avelumab concentration and diphenhydramine premedication use did not show a clinically meaningful effect on the QT interval. The frequency of QTc outliers in both short and long ranges was overestimated by local reads. Six patients (0.3%) were QTc outliers; all had either received concomitant medication known to cause QT prolongation or had a preexisting cardiac condition.

Conclusion: Avelumab does not have any clinically relevant effect on cardiac repolarization.

Keywords: Avelumab; Cancer; PD-L1; QT interval; QTc; Solid tumor.

PubMed Disclaimer

Conflict of interest statement

Y. Vugmeyster declares employment and patents with EMD Serono; H. Dai and M. Hennessy declare employment with EMD Serono; G. Güzel declares employment with Merck KGaA; A.H. Loos declares employment, patents, royalties, stock in, or other intellectual property with Merck KGaA.

Figures

Fig. 1
Fig. 1
Regression of a baseline QT interval vs baseline RR interval (n = 1780, P < 0.0001a, r = 0.7912), b baseline QTcF interval vs baseline RR interval (n = 1780, P < 0.0001a, r = 0.1982), or c baseline QTcP interval vs baseline RR interval (n = 1780, P =0.9024a, r = − 0.0029). QTcF, QTc derived from Fridericia’s formula; QTcP, QTc derived from a project-specific formula. aRefers to test of r = 0

Similar articles

Cited by

References

    1. Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561. doi: 10.3389/fphar.2017.00561. - DOI - PMC - PubMed
    1. Barkdull S, Brownell I. PD-L1 blockade with avelumab: a new paradigm for treating Merkel cell carcinoma. Cancer Biol Ther. 2017;18:937–939. doi: 10.1080/15384047.2017.1394552. - DOI - PMC - PubMed
    1. Liu B, Song Y, Liu D. Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy. J Hematol Oncol. 2017;10:174. doi: 10.1186/s13045-017-0541-9. - DOI - PMC - PubMed
    1. Heery CR, O’Sullivan-Coyne G, Madan RA, et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol. 2017;18:587–598. doi: 10.1016/S1470-2045(17)30239-5. - DOI - PMC - PubMed
    1. Bavencio (avelumab) (2019) [package insert]. Rockland, MA: EMD Serono

Publication types

MeSH terms